Skip to content
Cyber Threat
CTI Academy Sponsor CTI Academy
Ransomware victim Healthcare

Crystal Pharmatech

Listed by Eclipse on · organisation based in United States

www.crystalpharmatech.com

Disclosed
Aug 23, 2026
Leak-site listing date
Threat group
Eclipse
27 victims listed
Country
United States
#1 most targeted
Sector
Healthcare

ThreatAI analysis

Compiled from this incident record and the threat intelligence profile for Eclipse. Figures and technique mappings are quoted from the source data, not inferred.

Eclipse dark web leak site listed Crystal Pharmatech on 23 August 2026. Crystal Pharmatech is a CRO focusing on materials science and engineering for drug development.

About Crystal Pharmatech

Crystal Pharmatech is a technology-driven contract research organization (CRO) that focuses on materials science and engineering for drug development. Established in 2010 and have R&D centers located in Suzhou (China), New Jersey, San Francisco (USA), and Toronto (Canada). Also its key differentiator is integrated and specialized services, including API solid-state research, crystallization, preformulation, formulation development and manufacturing, clinical supply.

Source record: ransomware.live

About the Eclipse group

Eclipse has listed 19 victims since August 2026.

Incident analysis

Crystal Pharmatech was listed by Eclipse ransomware, a group with 27 victims recorded in this database. The listing appeared on the group's leak site on August 23, 2026.

Crystal Pharmatech is based in United States and operates in the Healthcare sector. United States ranks #1 worldwide for ransomware disclosures, with 10,305 victims in this database.

Sector context. Healthcare organisations are high-value ransomware targets because patient data is extremely sensitive, regulatory penalties for breaches are severe, and operational downtime can threaten patient safety — all factors that increase ransom payment pressure.

Eclipse typically follows a double extortion model: data is exfiltrated from the victim's systems before files are encrypted, so the victim faces two demands at once — pay to restore access, and pay to keep stolen data unpublished. The leak site, where this listing appeared, is the lever for the second demand.

Source. Public leak-site disclosures aggregated via the ransomware.live API. The disclosure date is when the listing was published, which can differ from the date of compromise. This site does not publish or link to stolen data. Last updated .

Frequently asked questions

Was Crystal Pharmatech attacked by ransomware?

Yes. Crystal Pharmatech was listed as a victim of the Eclipse ransomware group on August 23, 2026. The organisation is based in United States and operates in the Healthcare sector. The disclosure appeared on the group's dark web leak site.

Which ransomware group attacked Crystal Pharmatech?

Crystal Pharmatech was attacked by Eclipse ransomware. Eclipse is one of the most active ransomware groups, having claimed 27 victims globally. The group typically employs a double-extortion model: encrypting the victim's files and threatening to publish stolen data.

When did the Crystal Pharmatech ransomware attack occur?

The ransomware attack on Crystal Pharmatech was disclosed on August 23, 2026. This date reflects when the victim was published on the threat group's leak site, which may differ from the actual date of initial compromise.

What data was stolen in the Crystal Pharmatech ransomware attack?

The specific data stolen from Crystal Pharmatech has not been independently verified by this platform. Ransomware groups typically exfiltrate data before encrypting systems and use the threat of publication to pressure victims. As a Healthcare organisation, Crystal Pharmatech likely held patient records, medical data, and personally identifiable information (PII).

How can organisations protect against Eclipse attacks?

To defend against Eclipse and similar threat actors, organisations should: maintain regular offline backups tested for restoration; implement network segmentation to limit lateral movement; deploy multi-factor authentication on all remote access; use endpoint detection and response (EDR) tools; conduct regular phishing and security awareness training; and monitor threat intelligence feeds for indicators of compromise (IOCs) associated with active groups.